The European Commission is brooding on plans to allow pharmaceutical companies to have direct contact with patients about their drugs. Until now, this has been prohibited. Health groups in member states heavily oppose that business plan from the Directorate-General for Enterprise and Industry.
Can we expect pill manufacturers to provide objective information? That question begins a series of articles on the influence of the pharmaceutical industry in Europe.
The series received support from both Journalismfund's Pascal Decroos Fund and the Dutch Fonds Bijzondere Journalistieke Projecten.
